Aristotle Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14M Sell
64,146
-1,821
-3% -$404K 0.03% 127
2025
Q4
$15.1M Buy
65,967
+43
+0.1% +$9.79K 0.03% 127
2025
Q3
$15.3M Sell
65,924
-983
-1% -$200K 0.03% 130
2025
Q2
$12.4M Sell
66,907
-75
-0.1% -$13.9K 0.02% 128
2025
Q1
$14M Buy
66,982
+367
+0.6% +$71.3K 0.03% 124
2024
Q4
$11.8M Sell
66,615
-2,040
-3% -$375K 0.02% 131
2024
Q3
$13.6M Hold
68,655
0.02% 130
2024
Q2
$11.8M Sell
68,655
-73,248
-52% -$12.1M 0.02% 127
2024
Q1
$25.8M Buy
141,903
+144
+0.1% +$24.8K 0.05% 121
2023
Q4
$22M Buy
141,759
+73,800
+109% +$10.8M 0.04% 119
2023
Q3
$10.1M Sell
67,959
-1,020
-1% -$150K 0.02% 123
2023
Q2
$9.29M Sell
68,979
-6,815
-9% -$999K 0.02% 124
2023
Q1
$12.1M Sell
75,794
-8,168
-10% -$1.25M 0.03% 120
2022
Q4
$13.6M Buy
83,962
+8,579
+11% +$1.32M 0.03% 121
2022
Q3
$10.1M Buy
75,383
+187
+0.2% +$26.8K 0.02% 122
2022
Q2
$11.5M Sell
75,196
-104
-0.1% -$15.9K 0.02% 122
2022
Q1
$12.2M Sell
75,300
-100
-0.1% -$14.5K 0.02% 124
2021
Q4
$10.2M Buy
75,400
+11
+0% +$1.3K 0.02% 128
2021
Q3
$8.13M Buy
75,389
+112
+0.1% +$12.8K 0.02% 125
2021
Q2
$8.48M Sell
75,277
-1,200
-2% -$135K 0.02% 126
2021
Q1
$8.28M Sell
76,477
-103
-0.1% -$11K 0.02% 124
2020
Q4
$8.21M Sell
76,580
-14
-0% -$1.34K 0.02% 126
2020
Q3
$6.71M Buy
76,594
+9
+0% +$847 0.02% 121
2020
Q2
$7.52M Buy
76,585
+1
+0% +$88 0.03% 112
2020
Q1
$5.83M Sell
76,584
-2,780
-4% -$237K 0.02% 116
2019
Q4
$7.03M Sell
79,364
-15
-0% -$1.25K 0.02% 115
2019
Q3
$6.01M Sell
79,379
-4,262
-5% -$292K 0.03% 116
2019
Q2
$6.08M Sell
83,641
-635,257
-88% -$49.9M 0.03% 111
2019
Q1
$57.9M Sell
718,898
-2,325,371
-76% -$190M 0.34% 47
2018
Q4
$281M Sell
3,044,269
-430,667
-12% -$37.9M 1.89% 29
2018
Q3
$329M Sell
3,474,936
-649,633
-16% -$61.6M 1.91% 28
2018
Q2
$382M Buy
4,124,569
+336,696
+9% +$32.9M 2.35% 17
2018
Q1
$359M Buy
3,787,873
+34,727
+0.9% +$3.81M 2.41% 17
2017
Q4
$363M Sell
3,753,146
-879,600
-19% -$82.9M 2.52% 14
2017
Q3
$412M Buy
4,632,746
+3,854
+0.1% +$293K 3.2% 3
2017
Q2
$336M Buy
4,628,892
+102,269
+2% +$6.88M 2.8% 9
2017
Q1
$295M Buy
4,526,623
+154,719
+4% +$9.73M 2.68% 12
2016
Q4
$274M Buy
4,371,904
+176,116
+4% +$10.8M 2.59% 13
2016
Q3
$265M Sell
4,195,788
-48,523
-1% -$3.14M 2.75% 9
2016
Q2
$263M Buy
4,244,311
+89,306
+2% +$5.44M 2.85% 8
2016
Q1
$237M Buy
4,155,005
+133,367
+3% +$7.43M 2.75% 12
2015
Q4
$238M Buy
4,021,638
+140,989
+4% +$8.12M 2.87% 9
2015
Q3
$211M Buy
3,880,649
+163,173
+4% +$10.6M 2.64% 11
2015
Q2
$250M Sell
3,717,476
-36,110
-1% -$2.36M 2.94% 6
2015
Q1
$220M Buy
3,753,586
+196,282
+6% +$11.9M 2.73% 8
2014
Q4
$233M Sell
3,557,304
-24,455
-0.7% -$1.54M 2.98% 5
2014
Q3
$207M Buy
3,581,759
+173,512
+5% +$9.63M 2.72% 7
2014
Q2
$192M Buy
3,408,247
+163,734
+5% +$8.59M 2.56% 8
2014
Q1
$167M Buy
3,244,513
+127,372
+4% +$6.44M 2.42% 14
2013
Q4
$165M Buy
3,117,141
+734,991
+31% +$36.1M 2.62% 8
2013
Q3
$107M Buy
2,382,150
+525,610
+28% +$23.3M 2.13% 22
2013
Q2
$76.7M Buy
+1,856,540
New +$81.2M 2.11% 23

Other funds holding ABBV

Aristotle Capital Management's ABBV Position: Q1 2026 in Review

Aristotle Capital Management reduced its AbbVie (ABBV) stake by 2.8% in Q1 2026, selling an estimated $404K and leaving 64,146 shares worth $14M. The position accounts for 0.03% of the portfolio, ranked #127.

Aristotle Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $412M in Q3 2017. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Aristotle Capital Management held 64,146 shares of AbbVie worth $14M as of Q1 2026.
  • Aristotle Capital Management sold 1,821 AbbVie shares in Q1 2026, an estimated $404K.
  • AbbVie made up 0.03% of Aristotle Capital Management's portfolio in Q1 2026, its #127 holding.
  • Aristotle Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Aristotle Capital Management's AbbVie position peaked at $412M in Q3 2017.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Aristotle Capital Management's 13F filing for Q1 2026, filed 15 May 2026.